Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Nov 03 2023

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 4 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has announced a licensing agreement with Lupin for the co-marketing of Saroglitazar Mg, a treatment for chronic liver diseases in India. This innovative drug is approved for conditions such as Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steato Hepatitis, with Zydus continuing to market it under its own brand names. Lupin will market the drug under the brand name LINVAS and will pay Zydus licensing fees and milestone payments based on specific achievements. The partnership aims to enhance access to this critical treatment for patients suffering from these liver conditions in India.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 03, 2023, titled "Zydus and Lupin sign licensing agreement for co-marketing of Saroglitazar Mg, a critical treatment for chronic liver diseases in India".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases